Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1994 5
1995 11
1996 16
1997 14
1998 11
1999 16
2000 19
2001 41
2002 60
2003 61
2004 110
2005 115
2006 107
2007 122
2008 157
2009 148
2010 114
2011 141
2012 132
2013 132
2014 131
2015 110
2016 95
2017 118
2018 137
2019 99
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,962 results
Results by year
Filters applied: . Clear all
Page 1
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK. Berger T, et al. CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. CNS Drugs. 2017. PMID: 27882532 Free PMC article. Review.
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Kalincik T, et al. Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. Lancet Neurol. 2017. PMID: 28209331
Alemtuzumab for Multiple Sclerosis.
Willis MD, Robertson NP. Willis MD, et al. Curr Neurol Neurosci Rep. 2016 Sep;16(9):84. doi: 10.1007/s11910-016-0685-y. Curr Neurol Neurosci Rep. 2016. PMID: 27485945 Free PMC article. Review.
Alemtuzumab for multiple sclerosis.
Riera R, Porfírio GJ, Torloni MR. Riera R, et al. Cochrane Database Syst Rev. 2016 Apr 15;4(4):CD011203. doi: 10.1002/14651858.CD011203.pub2. Cochrane Database Syst Rev. 2016. PMID: 27082500 Free PMC article. Review.
Alemtuzumab for the treatment of multiple sclerosis.
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Evan JR, et al. Expert Opin Biol Ther. 2018 Mar;18(3):323-334. doi: 10.1080/14712598.2018.1425388. Expert Opin Biol Ther. 2018. PMID: 29309202 Review.
Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
Kim H, Lee EJ, Kim SK, Kim KK, Lim YM. Kim H, et al. Mult Scler Relat Disord. 2019 May;30:247-251. doi: 10.1016/j.msard.2019.03.001. Epub 2019 Mar 2. Mult Scler Relat Disord. 2019. PMID: 30849681
Alemtuzumab as Treatment for Multiple Sclerosis.
Katsavos S, Coles A. Katsavos S, et al. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029. doi: 10.1101/cshperspect.a032029. Cold Spring Harb Perspect Med. 2018. PMID: 29500306 Free PMC article. Review.
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
Alcalá C, Gascón F, Pérez-Miralles F, Domínguez JA, Gil-Perotín S, Casanova B. Alcalá C, et al. J Neurol. 2019 Mar;266(3):726-734. doi: 10.1007/s00415-019-09195-2. Epub 2019 Jan 19. J Neurol. 2019. PMID: 30661133 Clinical Trial.
1,962 results
Jump to page
Feedback